Drugs / Vesleteplirsen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04004065 | Jun 2019 → Oct 2023 | Duchenne muscular dystrophy | Sarepta Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vesleteplirsen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04004065 ↗ |
| Route | Intravenous | “Vesleteplirsen injection, for IV use” NCT04004065 ↗ |